Abstract
Access is the number one issue facing psoriasis patients today. This is due in part to the fact that we do not have outcome measures that are useful in clinical practice and which are available in standard clinical care databases that payers and governmental agencies use to compare the performance of physicians and treatments. The International Dermatology Outcomes Measures (IDEOM) group includes all willing stakeholders – patients, physicians, payers, and pharmaceutical scientists. Its goal is to develop outcome measures in dermatology which address the needs of all stakeholders. For our first project, Delphi analyses of psoriasis outcomes will be performed among doctors and patients.
Get full access to this article
View all access options for this article.